Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of venous Chronic Venous Insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg; and enVVe, a non-surgical, transcatheter based replacement venous valve for the treatment of CVI. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California. more
Time Frame | NVNO | Sector | S&P500 |
---|---|---|---|
1-Week Return | -12.63% | -2.12% | -3% |
1-Month Return | -26.11% | -3.42% | -0.73% |
3-Month Return | -47.58% | -11.13% | 2.87% |
6-Month Return | -46.68% | -5.74% | 7.17% |
1-Year Return | -45.51% | 3.97% | 25.31% |
3-Year Return | -62.84% | 1.05% | 28.38% |
5-Year Return | -76.84% | 34.37% | 81.89% |
10-Year Return | -98.1% | 97.88% | 183.27% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 31.24K | - | - | - | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | - | 383.97K | 452.91K | 525.00K | 546.00K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":70.32,"profit":true},{"date":"2021-12-31","value":82.95,"profit":true},{"date":"2022-12-31","value":96.15,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 31.24K | (383.97K) | (452.91K) | (525.00K) | (546.00K) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-1228.99,"profit":false},{"date":"2021-12-31","value":-1449.63,"profit":false},{"date":"2022-12-31","value":-1680.38,"profit":false},{"date":"2023-12-31","value":-1747.59,"profit":false}] |
Gross Margin | 100.00% | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] |
Operating Expenses | 7.12M | 9.14M | 16.89M | 24.93M | 25.24M | [{"date":"2019-12-31","value":28.2,"profit":true},{"date":"2020-12-31","value":36.2,"profit":true},{"date":"2021-12-31","value":66.93,"profit":true},{"date":"2022-12-31","value":98.79,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (7.68M) | (9.14M) | (16.89M) | (24.93M) | (25.24M) | [{"date":"2019-12-31","value":-767531200,"profit":false},{"date":"2020-12-31","value":-913512600,"profit":false},{"date":"2021-12-31","value":-1689250300,"profit":false},{"date":"2022-12-31","value":-2493200000,"profit":false},{"date":"2023-12-31","value":-2523800000,"profit":false}] |
Total Non-Operating Income/Expense | 99.83K | 3.38K | 383.39K | 424.00K | 1.89M | [{"date":"2019-12-31","value":5.27,"profit":true},{"date":"2020-12-31","value":0.18,"profit":true},{"date":"2021-12-31","value":20.24,"profit":true},{"date":"2022-12-31","value":22.39,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (7.63M) | (9.14M) | (16.53M) | (24.67M) | (23.52M) | [{"date":"2019-12-31","value":-762539700,"profit":false},{"date":"2020-12-31","value":-913548600,"profit":false},{"date":"2021-12-31","value":-1652782200,"profit":false},{"date":"2022-12-31","value":-2466900000,"profit":false},{"date":"2023-12-31","value":-2351600000,"profit":false}] |
Income Taxes | 588.82K | (215.55K) | (331.41K) | (365.00K) | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-36.61,"profit":false},{"date":"2021-12-31","value":-56.28,"profit":false},{"date":"2022-12-31","value":-61.99,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (8.21M) | (8.92M) | (16.20M) | (24.30M) | - | [{"date":"2019-12-31","value":-821421900,"profit":false},{"date":"2020-12-31","value":-891994000,"profit":false},{"date":"2021-12-31","value":-1619641300,"profit":false},{"date":"2022-12-31","value":-2430400000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (7.63M) | (9.14M) | (16.53M) | (24.67M) | (24.05M) | [{"date":"2019-12-31","value":-762539700,"profit":false},{"date":"2020-12-31","value":-913548600,"profit":false},{"date":"2021-12-31","value":-1652782200,"profit":false},{"date":"2022-12-31","value":-2466900000,"profit":false},{"date":"2023-12-31","value":-2404700000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (7.63M) | (8.92M) | (16.20M) | (24.30M) | (23.52M) | [{"date":"2019-12-31","value":-762539700,"profit":false},{"date":"2020-12-31","value":-891994000,"profit":false},{"date":"2021-12-31","value":-1619641300,"profit":false},{"date":"2022-12-31","value":-2430400000,"profit":false},{"date":"2023-12-31","value":-2351600000,"profit":false}] |
EPS (Diluted) | (6.01) | (3.85) | (1.96) | (2.19) | (1.96) | [{"date":"2019-12-31","value":-601,"profit":false},{"date":"2020-12-31","value":-385,"profit":false},{"date":"2021-12-31","value":-196,"profit":false},{"date":"2022-12-31","value":-219,"profit":false},{"date":"2023-12-31","value":-196,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
NVNO | |
---|---|
Cash Ratio | 21.70 |
Current Ratio | 22.01 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
NVNO | |
---|---|
ROA (LTM) | -37.28% |
ROE (LTM) | -58.77% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
NVNO | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.06 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.94 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
NVNO | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 0.93 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
enVVeno Medical Corp (NVNO) share price today is $2.49
Yes, Indians can buy shares of enVVeno Medical Corp (NVNO) on Vested. To buy enVVeno Medical Corp from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in NVNO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of enVVeno Medical Corp (NVNO) via the Vested app. You can start investing in enVVeno Medical Corp (NVNO) with a minimum investment of $1.
You can invest in shares of enVVeno Medical Corp (NVNO) via Vested in three simple steps:
The 52-week high price of enVVeno Medical Corp (NVNO) is $6.97. The 52-week low price of enVVeno Medical Corp (NVNO) is $2.45.
The price-to-earnings (P/E) ratio of enVVeno Medical Corp (NVNO) is
The price-to-book (P/B) ratio of enVVeno Medical Corp (NVNO) is 0.93
The dividend yield of enVVeno Medical Corp (NVNO) is 0.00%
The market capitalization of enVVeno Medical Corp (NVNO) is $44.37M
The stock symbol (or ticker) of enVVeno Medical Corp is NVNO